Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$92.48+3.18 (+3.56%)
Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%
Dianthus Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Dianthus Therapeutics's total assets was $1.28B at Sep 30, 2026. For fiscal 2025 it was $530.92M, up 42.0% from the year before. The highest annual figure on record is $530.92M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $530.92M | +42.0% |
| FY2024 | Dec 31, 2024 | $374.01M | +108.5% |
| FY2023 | Dec 31, 2023 | $179.41M | +115.9% |
| FY2022 | Dec 31, 2022 | $83.11M | -56.2% |
| FY2021 | Dec 31, 2021 | $189.93M | +17.5% |
| FY2020 | Dec 31, 2020 | $161.62M | +0.1% |
| FY2019 | Dec 31, 2019 | $161.51M | +2.7% |
| FY2018 | Dec 31, 2018 | $157.31M | +188.8% |
| FY2017 | Dec 31, 2017 | $54.46M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.28B | +121.0% |
| Q2 FY2026 | Jun 30, 2026 | $1.21B | +272.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.25B | +257.7% |
| Q4 FY2025 | Dec 31, 2025 | $530.92M | +42.0% |
| Q3 FY2025 | Sep 30, 2025 | $577.45M | +63.0% |
| Q2 FY2025 | Jun 30, 2025 | $326.08M | -11.6% |
| Q1 FY2025 | Mar 31, 2025 | $348.58M | -8.9% |
| Q4 FY2024 | Dec 31, 2024 | $374.01M | +108.5% |
| Q3 FY2024 | Sep 30, 2024 | $354.25M | +84.1% |
| Q2 FY2024 | Jun 30, 2024 | $368.96M | +369.2% |
| Q1 FY2024 | Mar 31, 2024 | $382.46M | +358.4% |
| Q4 FY2023 | Dec 31, 2023 | $179.41M | +115.9% |
| Q3 FY2023 | Sep 30, 2023 | $192.46M | +17.3% |
| Q2 FY2023 | Jun 30, 2023 | $78.64M | -55.1% |
| Q1 FY2023 | Mar 31, 2023 | $83.44M | -57.1% |
| Q4 FY2022 | Dec 31, 2022 | $83.11M | -56.2% |
| Q3 FY2022 | Sep 30, 2022 | $164.12M | -20.4% |
| Q2 FY2022 | Jun 30, 2022 | $175.12M | -20.5% |
| Q1 FY2022 | Mar 31, 2022 | $194.39M | +34.4% |
| Q4 FY2021 | Dec 31, 2021 | $189.93M | +17.5% |
| Q3 FY2021 | Sep 30, 2021 | $206.24M | +18.1% |
| Q2 FY2021 | Jun 30, 2021 | $220.38M | +15.5% |
| Q1 FY2021 | Mar 31, 2021 | $144.62M | +0.1% |
| Q4 FY2020 | Dec 31, 2020 | $161.62M | +0.1% |
| Q3 FY2020 | Sep 30, 2020 | $174.64M | -1.5% |
| Q2 FY2020 | Jun 30, 2020 | $190.73M | -2.4% |
| Q1 FY2020 | Mar 31, 2020 | $144.44M | -2.2% |
| Q4 FY2019 | Dec 31, 2019 | $161.51M | +2.7% |
| Q3 FY2019 | Sep 30, 2019 | $177.23M | +2.6% |
| Q2 FY2019 | Jun 30, 2019 | $195.44M | +8.2% |
| Q1 FY2019 | Mar 31, 2019 | $147.69M | +171.2% |
| Q4 FY2018 | Dec 31, 2018 | $157.31M | – |
| Q3 FY2018 | Sep 30, 2018 | $172.79M | – |
| Q2 FY2018 | Jun 30, 2018 | $180.62M | – |
| Q4 FY2017 | Dec 31, 2017 | $54.46M | – |
See a number that looks wrong?